Incyte Business Segments — Net Income increased by 1.4% to $303.33M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 91.7%, from $158.20M to $303.33M. Over 3 years (FY 2022 to FY 2025), Business Segments — Net Income shows an upward trend with a 55.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates improved operational efficiency or higher product margins, while a decrease suggests rising costs or declining revenue performance.
This represents the total profit generated by the primary business segment after accounting for all operating expenses,...
Standard across pharmaceutical firms, though comparability depends on how companies allocate corporate overhead and R&D to specific segments.
incy_segment_reportable_segment_net_income| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $85.17M | $85.17M | $85.17M | $85.17M | $149.40M | $149.40M | $149.40M | $149.40M | $169.55M | -$444.60M | $106.46M | $201.21M | $158.20M | $405.00M | $424.17M | $299.28M | $303.33M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +75.4% | +0.0% | +0.0% | +0.0% | +13.5% | -362.2% | +123.9% | +89.0% | -21.4% | +156.0% | +4.7% | -29.4% | +1.4% |
| YoY Change | — | — | — | — | +75.4% | +75.4% | +75.4% | +75.4% | +13.5% | -397.6% | -28.7% | +34.7% | -6.7% | +191.1% | +298.4% | +48.7% | +91.7% |